All posts from Andreas
Andreas in Insider trading,

AbbVie releases strong report

AbbVie (ABBV), a major US biopharmaceutical company producing drugs to treat rheumatoid arthritis, Parkinson's disease, HIV, hepatitis C and other, released a strong financial report for 3Q15. Revenue jumped 18% y-o-y to USD 5.94 bn. Sales of Humira (main product of the company, which provides 61% of all sales, intended to treat psoriasis and rheumatoid arthritis) were up 12% y-o-y. Sales of Viekira (a drug to treat hepatitis C launched in production this year) rose to USD 469 mn. This drug is similar to the drug of Gilead, however, it is less efficient. Adjusted EPS spiked 27% y-o-y to USD 1.13, outpacing forecasts by 6%. Strong results in Q3 allowed AbbVie to upgrade EPS forecast for 2015 from USD 4.10-4.30 to USD 4.26-4.28. The company raised quarterly dividend from 51 cents to 57 cents (+12% q-o-q), yielding 3.8%.

We are still upbeat about shares of AbbVie. In our opinion, the company has strong portfolio of drugs and it also continues to develop and launch into production new ones. We believe that AbbVie provides attractive investment opportunity in the mid-term and assign a Buy recommendation to the name.